USANA Health Sciences (NYSE:USNA) Director John Turman Fleming Sells 2,450 Shares

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 2,450 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the sale, the director owned 4,230 shares in the company, valued at $75,843.90. The trade was a 36.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

USANA Health Sciences Price Performance

NYSE:USNA traded down $0.04 during trading hours on Monday, reaching $18.26. 132,203 shares of the stock were exchanged, compared to its average volume of 125,823. The stock has a market cap of $337.12 million, a PE ratio of 38.86, a PEG ratio of 0.72 and a beta of 0.77. USANA Health Sciences, Inc. has a twelve month low of $16.60 and a twelve month high of $38.32. The firm has a 50 day moving average of $18.31 and a 200 day moving average of $19.47.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. The business had revenue of $250.22 million for the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Equities research analysts anticipate that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current year.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors have recently made changes to their positions in USNA. National Bank of Canada FI increased its stake in shares of USANA Health Sciences by 166.6% during the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares during the period. Tower Research Capital LLC TRC boosted its stake in USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares during the period. State of Wyoming acquired a new position in USANA Health Sciences in the 1st quarter valued at $57,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after buying an additional 1,327 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in USANA Health Sciences by 1,354.3% during the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after buying an additional 3,589 shares during the period. Institutional investors own 54.25% of the company’s stock.

Analysts Set New Price Targets

USNA has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.